Faeth Therapeutics, Inc. — Form 8-K
Filed November 9, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 78/100
What the filing says
Faeth Therapeutics announced topline results from PIK-201, a Phase 2 single-arm study of PIKTOR (serabelisib + sapanisertib) plus paclitaxel in 42 patients with platinum- and immunotherapy-pretreated endometrial cancer. Confirmed objective response rate was 33% (12 of 36 efficacy-evaluable patients); median PFS 7.4 months; disease control rate 83%. Among PIK3CA-mutant patients (n unspecified), confirmed ORR was 44% and DCR 81%. Safety profile showed low PAM-class toxicity: hyperglycemia 12% (2% grade 3), stomatitis 21% (2% grade 3); only 5% discontinued for treatment-related adverse events. Company plans Phase 3 trial design disclosure in H1 2027.
Why this rating
Early-stage clinical success in an orphan indication with significant unmet need; establishes potential regulatory pathway. However, company scale ($7.1M market cap) is microscopic; even Phase 3 initiation carries execution risk and years to monetization.
Tradability signal
NO TRADE
No trade: the filing reads positive but the market is selling it (-27.8% since it hit EDGAR) — when our read and the tape disagree this hard, we stand aside. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $17.75 ▲ 33.06% | at our read · unknown $13.34 | +10 min · unknown $12.23 ▼ 8.32% | +30 min · unknown $12.19 ▼ 8.66% | +1 hr · unknown $11.27 ▼ 15.52% | +4 hrs · unknown $12.32 ▼ 7.65% |
The stock had already moved -24.85% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 9, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.